特利加压素联合托伐普坦治疗乙型肝炎肝硬化并发肝肾综合征的疗效

betway必威登陆网址（betway.com ）学报››2022,Vol. 43››Issue (10): 770-773.DOI:10.3969/j.issn.2097-0005.2022.10.009

特利加压素联合托伐普坦治疗乙型肝炎肝硬化并发肝肾综合征的疗效

聂翠芳¹(), 赵传芸¹, 杨圣强²()

^1.泰安市中心医院，感染科，山东泰安 271000
^2.泰安市中心医院，麻醉科，山东泰安 271000

收稿日期:2022-04-06出版日期:2022-10-25发布日期:2022-11-19
通讯作者:杨圣强
作者简介:聂翠芳，硕士，副主任医师，研究方向：肝病及感染性疾病的诊治，E-mail：ncf060721@163.com。

Therapeutic effect analysis of terlipressin combined with torvaptan in the treatment of hepatitis B cirrhosis complicated hepatorenal syndrome

Cuifang NIE¹(), Chuanyun ZHAO¹, Shengqiang YANG²()

^1.Department of Infection, Taian City Central Hospital，Taian 271000，China
^2.Department of Anesthesiology, Taian City Central Hospital，Taian 271000，China

Received:2022-04-06Online:2022-10-25Published:2022-11-19
Contact:Shengqiang YANG

摘要/Abstract

摘要：

目的探讨特利加压素联合托伐普坦治疗乙型肝炎肝硬化并发肝肾综合征的效果。方法选择2016年1月至2019年12月住院的乙型肝炎肝硬化并发肝肾综合征患者60例，随机分为观察组和对照组各30例，两组患者均行抗病毒、抗纤维化、保肝等基础治疗，对照组给予呋塞米、螺内酯基础利尿剂治疗，观察组给予特利加压素联合托伐普坦治疗，疗程均为2周，观察两组患者治疗前后24 h尿量和血肌酐、尿素氮、胱抑素C、Na⁺水平以及门静脉主干内径和血流量变化。结果治疗前两组患者24 h尿量和血肌酐、尿素氮、胱抑素C、Na⁺浓度以及门静脉主干内径、血流量的变化不明显，差异均无统计学意义（P> 0.05）；治疗后观察组患者24 h尿量明显增加，血中的尿素氮、肌酐以及胱抑素C水平下降明显，血中Na⁺浓度明显升高，门静脉主干内径及血流量均明显降低，所有指标变化均显著优于对照组，差异有统计学意义（P< 0.05）。结论特利加压素联合托伐普坦能有效改善乙型肝炎肝硬化并发肝肾综合征患者的肾功能，纠正低钠血症并降低门静脉压力。

关键词:乙型肝炎肝硬化,肝肾综合征,特利加压素,托伐普坦

Abstract:

ObjectiveTo investigate the effect of terlipressin combined with torvaptan in the treatment of hepatitis B cirrhosis complicated hepatorenal syndrome.MethodsA total of 60 patients with hepatitis B cirrhosis complicated hepatorenal syndrome who were hospitalized from January 2016 to December 2019 were randomly divided into observation group and control group with 30 patients in each group. Patients in both groups were routinely treated with antiviral， anti-liver fibrosis and liver-protecting treatment， the control group was given furosemide and spironolactone based diuretic treatment， and the observation group was given terlipressin combined with torvaptam treatment， in a course of 2 weeks. 24 h urine volume， serum creatinine， urea nitrogen， cystatin C， Na⁺levels， portal trunk diameter and blood flow were detected before and after treatment respectively in the two groups.ResultsBefore treatment， there was no statistical significance in 24 h urine volume， serum creatinine， urea nitrogen， cystatin C， Na⁺concentrations， portal trunk diameter and blood flow in 2 groups （P> 0.05）； After treatment， 24 h urine volume in observation group was significantly increased， serum creatinine， urea nitrogen， cystatin C levels were significantly decreased， Na⁺concentration was significantly increased， portal trunk diameter and blood flow were significantly decreased， and all indexes were significantly better than those in control group （P< 0.05）.ConclusionTerlipressin combined with tolvaptam can effectively improve renal function， correct hyponatremia and reduce portal pressure in patients with hepatitis B cirrhosis complicated hepatorenal syndrome.

Key words:hepatitis B cirrhosis,hepatorenal syndrome,terlipressin,torvaptan

聂翠芳, 赵传芸, 杨圣强. 特利加压素联合托伐普坦治疗乙型肝炎肝硬化并发肝肾综合征的疗效[J]. betway必威登陆网址（betway.com ）学报, 2022, 43(10): 770-773.

Cuifang NIE, Chuanyun ZHAO, Shengqiang YANG. Therapeutic effect analysis of terlipressin combined with torvaptan in the treatment of hepatitis B cirrhosis complicated hepatorenal syndrome[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(10): 770-773.

图/表4

组别	n	治疗前	治疗后	t	P
观察组	30	732.6 ± 151.9	2475.7 ± 190.5	47.278	< 0.001
对照组	30	747.2 ± 153.5	822.5 ± 164.3	1.834	0.072
t		0.370	35.995
P		0.713	< 0.001

组别	n	治疗前	治疗后	t	P
观察组	30	732.6 ± 151.9	2475.7 ± 190.5	47.278	< 0.001
对照组	30	747.2 ± 153.5	822.5 ± 164.3	1.834	0.072
t		0.370	35.995
P		0.713	< 0.001

组别	n	Cys C（mg/L）	Na⁺（mmol/L）
观察组	30	3.12 ± 1.30	1.38 ± 0.35	7.079	< 0.001	129.5 ± 6.9	137.1 ± 9.2	3.620	0.001
对照组	30	3.29 ± 1.23	3.08 ± 1.12	0.691	0.492	130.1 ± 7.2	131.6 ± 6.8	0.830	0.410
t		0.520	7.935			0.330	2.633
P		0.605	< 0.001			0.743	0.011

组别	n	Cys C（mg/L）	Na⁺（mmol/L）
观察组	30	3.12 ± 1.30	1.38 ± 0.35	7.079	< 0.001	129.5 ± 6.9	137.1 ± 9.2	3.620	0.001
对照组	30	3.29 ± 1.23	3.08 ± 1.12	0.691	0.492	130.1 ± 7.2	131.6 ± 6.8	0.830	0.410
t		0.520	7.935			0.330	2.633
P		0.605	< 0.001			0.743	0.011

组别	n	Scr（µmol/L）	BUN（mmol/L）
观察组	30	181.15 ± 45.23	116.17 ± 68.24	4.347	< 0.001	15.85 ± 2.89	7.16 ± 3.05	11.328	< 0.001
对照组	30	183.21 ± 50.16	169.20 ± 69.15	0.898	0.373	16.10 ± 2.78	15.15 ± 2.89	1.298	0.200
t		0.167	2.990			0.341	10.415
P		0.868	0.004			0.734	< 0.001

组别	n	Scr（µmol/L）	BUN（mmol/L）
观察组	30	181.15 ± 45.23	116.17 ± 68.24	4.347	< 0.001	15.85 ± 2.89	7.16 ± 3.05	11.328	< 0.001
对照组	30	183.21 ± 50.16	169.20 ± 69.15	0.898	0.373	16.10 ± 2.78	15.15 ± 2.89	1.298	0.200
t		0.167	2.990			0.341	10.415
P		0.868	0.004			0.734	< 0.001

组别	n	DPV（mm）	QPV（mL/s）
观察组	30	15.16 ± 1.89	12.21 ± 2.95	4.612	< 0.001	15.48 ± 5.10	11.98 ± 4.06	2.941	0.005
对照组	30	14.98 ± 1.72	14.79 ± 1.81	0.305	0.762	15.61 ± 5.32	15.12 ± 5.07	0.365	0.716
t		0.386	4.083			0.097	2.648
P		0.701	< 0.001			0.923	0.010

组别	n	DPV（mm）	QPV（mL/s）
观察组	30	15.16 ± 1.89	12.21 ± 2.95	4.612	< 0.001	15.48 ± 5.10	11.98 ± 4.06	2.941	0.005
对照组	30	14.98 ± 1.72	14.79 ± 1.81	0.305	0.762	15.61 ± 5.32	15.12 ± 5.07	0.365	0.716
t		0.386	4.083			0.097	2.648
P		0.701	< 0.001			0.923	0.010

参考文献14

1	Li Y， Qi XS， Li HY， et al. D-dimer level for predicting the in-hospital mortality in liver cirrhosis： a retrospective study［J］. Exp Ther Med， 2017， 13（1）： 285.
2	许海苗. 肝硬化失代偿期并发肝性胸水56例临床观察［J］. 肝脏， 2016， 21（3）： 229.
3	王小华，王伟，张妮，等. 血清NGAL联合肌酐早期判断乙型肝炎肝硬化患者并发肝肾综合征的临床价值分析［J］. 实用肝脏病杂志， 2018， 21（5）： 685.
4	陈红萍. 特利加压素联合中药治疗顽固性腹水的临床观察［J］. 临床医学研究与实践， 2016， 1（3）： 28.
5	Tanaka A， Hiramatsu E， Watanabe Y， et al. Efficacy of long-term treatment with tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure［J］. Ther Apher Dial， 2019， 23（4）： 319.
6	中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南［J］. 临床肝胆病杂志， 2017， 33（10）： 1847.
7	武瑞，刘春涛，武静，等. 非选择性β受体阻滞剂对肝硬化合并食管-胃底静脉曲张患者血流动力学及肝肾综合征发生情况的影响［J］. 中国全科医学， 2019， 22（6）： 678.
8	Mattos ÂZ， Mattos AA， Ribeiro RA. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome： systematic review with meta-analysis and full economic evaluation［J］. Eur J Gastroenterol Hepatol， 2016， 28（3）： 345.
9	Barnes A， Cock C. Rapid reversal of hyponatraemia in a patient with non-cirrhotic portal hypertension treated with terlipressin［J］. Intern Med J， 2020， 50（2）： 254.
10	Facciorusso A， Chandar AK， Murad MH， et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome： a systematic review and network meta-analysis［J］. Lancet Gastroenterol Hepatol， 2017， 2（2）： 94.
11	Cavallin M， Piano S， Romano A， et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome： a randomized controlled study［J］. Hepatology， 2016， 63（3）： 983.
12	齐菲，张士红. 选择性AVP受体拮抗剂托伐普坦的药理及应用评价［J］. 医学与哲学（B）， 2016， 37（2）： 63.
13	Katsumata M， Hirawa N， Sumida K， et al. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure［J］. Clin Exp Nephrol， 2017， 21（5）： 858.
14	Tominaga N， Kida K， Inomata T， et al. Effects of tolvaptan addition to furosemide in normo- and hyponatremia patients with heart failure and chronic kidney disease stages G3b-5： a subanalysis of the K-STAR study［J］. Am J Nephrol， 2017， 46（5）： 417.